Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Himanshu AGGARWAL |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
PDE3 inhibition by cilostazol attenuated developmental hyperserotonemia induced behavioural and biochemical deficits in a rat model of autism spectrum disorder / Kanishk LUHACH in Research in Autism Spectrum Disorders, 99 (November)
[article]
Titre : PDE3 inhibition by cilostazol attenuated developmental hyperserotonemia induced behavioural and biochemical deficits in a rat model of autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Kanishk LUHACH, Auteur ; Bhagwat SINGH, Auteur ; Himanshu AGGARWAL, Auteur ; Bhupesh SHARMA, Auteur Article en page(s) : 102052 Langues : Anglais (eng) Mots-clés : Developmental hyperserotonemia Phosphodiesterase 3 BDNF Neuroinflammation Oxidative stress Index. décimale : PER Périodiques Résumé : Background Hyperserotonemia, in the early developmental phase generates behavioural and biochemical phenotypes associated with autism spectrum disorder (ASD) in rats. Phosphodiesterase-3 (PDE3) inhibition by cilostazol has been shown to provide benefits in various brain conditions. We investigated the role of a selective PDE3 inhibitor cilostazol on ASD related behavioural phenotypes. Method Administration of 5-Methoxytryptamine (5-MT) to rats perinatally (GD12-Parturition) and in early developmental stages (PND0-PND20), resulted into developmental hyperserotonemia (DHS). DHS associated behavioural changes (social behaviour deficits, repetitive behaviour, anxiety and hyperlocomotion) were assessed using a battery of behavioural examinations. Also, effect on biochemical markers related with neuronal function (BDNF - neuronal survival and pCREB - neuronal transcription factor), inflammation (IL-6, IL-10 and TNF-Î+) and oxidative stress (TBARS and GSH) were studied in important brain areas (frontal cortex, cerebellum, hippocampus, and striatum). Cilostazol was administered in two doses 30 & 60Â mg.kg-1 p.o. each day to male rats from PND21 to PND48. Result Administration of cilostazol to 5-MT rats resulted in improvement of behavioural deficits. Also, cilostazol administration significantly increased the levels of BDNF, pCREB, IL-10, GSH and significantly decreased TNF-Î+, IL-6 and TBARS levels in different brain areas. Conclusion DHS during prenatal and early postnatal developmental stages leads to pervasive harm to the serotonergic system, leading to prolonged effects as observed via behavioural and biochemical outcomes of the study. Serotonin regulates early brain neurogenesis, synaptogenesis, and neuronal differentiation probably via the CREB/BDNF pathway and DHS is known to reduce the activity of CREB/BDNF pathway. Cilostazol administration to pups exposed to DHS perinatally has resulted in increase of neurotrophic factors, reduced inflammation and reduced oxidative stress, probably via increased cAMP/CREB/BDNF signalling. Also, improvement in behavioural profile of animals subjected to DHS. Thus, PDE3 and its inhibitors could be considered as molecules of interest for research in developmental disorders. En ligne : https://doi.org/10.1016/j.rasd.2022.102052 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490
in Research in Autism Spectrum Disorders > 99 (November) . - 102052[article] PDE3 inhibition by cilostazol attenuated developmental hyperserotonemia induced behavioural and biochemical deficits in a rat model of autism spectrum disorder [Texte imprimé et/ou numérique] / Kanishk LUHACH, Auteur ; Bhagwat SINGH, Auteur ; Himanshu AGGARWAL, Auteur ; Bhupesh SHARMA, Auteur . - 102052.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 99 (November) . - 102052
Mots-clés : Developmental hyperserotonemia Phosphodiesterase 3 BDNF Neuroinflammation Oxidative stress Index. décimale : PER Périodiques Résumé : Background Hyperserotonemia, in the early developmental phase generates behavioural and biochemical phenotypes associated with autism spectrum disorder (ASD) in rats. Phosphodiesterase-3 (PDE3) inhibition by cilostazol has been shown to provide benefits in various brain conditions. We investigated the role of a selective PDE3 inhibitor cilostazol on ASD related behavioural phenotypes. Method Administration of 5-Methoxytryptamine (5-MT) to rats perinatally (GD12-Parturition) and in early developmental stages (PND0-PND20), resulted into developmental hyperserotonemia (DHS). DHS associated behavioural changes (social behaviour deficits, repetitive behaviour, anxiety and hyperlocomotion) were assessed using a battery of behavioural examinations. Also, effect on biochemical markers related with neuronal function (BDNF - neuronal survival and pCREB - neuronal transcription factor), inflammation (IL-6, IL-10 and TNF-Î+) and oxidative stress (TBARS and GSH) were studied in important brain areas (frontal cortex, cerebellum, hippocampus, and striatum). Cilostazol was administered in two doses 30 & 60Â mg.kg-1 p.o. each day to male rats from PND21 to PND48. Result Administration of cilostazol to 5-MT rats resulted in improvement of behavioural deficits. Also, cilostazol administration significantly increased the levels of BDNF, pCREB, IL-10, GSH and significantly decreased TNF-Î+, IL-6 and TBARS levels in different brain areas. Conclusion DHS during prenatal and early postnatal developmental stages leads to pervasive harm to the serotonergic system, leading to prolonged effects as observed via behavioural and biochemical outcomes of the study. Serotonin regulates early brain neurogenesis, synaptogenesis, and neuronal differentiation probably via the CREB/BDNF pathway and DHS is known to reduce the activity of CREB/BDNF pathway. Cilostazol administration to pups exposed to DHS perinatally has resulted in increase of neurotrophic factors, reduced inflammation and reduced oxidative stress, probably via increased cAMP/CREB/BDNF signalling. Also, improvement in behavioural profile of animals subjected to DHS. Thus, PDE3 and its inhibitors could be considered as molecules of interest for research in developmental disorders. En ligne : https://doi.org/10.1016/j.rasd.2022.102052 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490